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CRC that recapitulates the sessile serrated adenoma-carcinoma pathway in humans. In conjunction with in vitro cell line studies, we used this GEMM to identify continued PI3K/mTOR signaling as a potential resistance mechanism and to demonstrate the efficacy of concomitant BRAF and PI3K/mTOR blockade for therapy. Taken together, this GEMM provides a robust preclinical platform to interrogate BRAF
V600E

Introduction
BRAF is a critical component of the mitogen-activated protein kinase (MAPK) signaling pathway. 1 
BRAF
V600E
mutations have been identified in melanoma, papillary thyroid carcinoma, and CRC, and result in constitutive MAPK signaling that promotes carcinogenesis. 2 
BRAF V600E
mutations are seen in 15% of CRC and are associated with decreased survival. 3 In particular, microsatellite stable (MSS) BRAF V600E CRC is associated with these poor clinical outcomes. 4 With respect to CRC with high microsatellite instability (MSI-H) in the adjuvant setting (mainly stage II and III CRC), patients have better outcomes and the presence of BRAF mutation does not affect outcomes. 5 However, in the setting of metastatic tumor, BRAF V600E /MSI-H tumors have poorer outcomes than BRAF wild-type/MSI-H tumors. 6, 7 As more than 600,000 people worldwide die from CRC each year, robust therapies targeting MSS BRAF V600E CRC is a critical unmet clinical need. 8 The development of selective BRAF inhibitors is a compelling goal for drug discovery. 9 For instance, a recent phase III melanoma clinical trial resulted in a 48% response following treatment with the BRAF inhibitor PLX4032 (vemurafenib) versus 5% for standard of care dacarbazine chemotherapy. 10 However, acquired resistance to vemurafenib quickly emerges. 11, 12 Potential resistance mechanisms include: 1) secondary mutations in RAS, HRAS, NRAS, or MEK1; 2) activation of COT-1 kinase; and 3) induction of PI3K/mTOR signaling through recruitment of PDGFR or IGF-1R.
CRC treatment with BRAF inhibitors has been disappointing. For example, vemurafenib treatment in 19 BRAF
V600E
CRC patients yielded only one partial and four minor responses.
Furthermore, five patients presented with a mixed response pattern of both regressing and progressing lesions. 17 Whereas these results highlight the therapeutic potential for such BRAF inhibitors, they underscore the presence of molecular features in BRAF
CRC that restrict their clinical efficacy. Unlike melanoma, initiation of CRC carcinogenesis derives from perturbation of Wnt signaling. 18 As such, one hypothesis for the disparate clinical responses in melanoma and CRC could include the recruitment of additional signaling pathways. Indeed, two recent publications have reported a mechanism in BRAF V600E CRC that following BRAFinhibition, phospho-EGFR activity increases leading to reactivation of the MAPK pathway. 19, 20 Whereas PI3K/mTOR signaling has been implicated in resistance to BRAF inhibitors in melanoma, it also plays a dominant role in CRC carcinogenesis, being constitutively activated in approximately 30% of all patients. 21 However, 60% of BRAF
CRCs have been reported to have increased p-AKT expression, suggesting that the PI3K/mTOR axis is activated in a significant proportion of BRAF V600E CRC. 22 Taken together, these findings suggest that PI3K/mTOR signaling may represent a significant resistance mechanism to BRAF inhibitor treatment in BRAF V600E CRC.
We have described multiple novel genetically engineered mouse models (GEMMs) for sporadic CRC. 23, 24 These GEMMs are ideally suited for preclinical trials, using optical colonoscopy to assess dynamic tumor responses to treatment. In our studies, we used in vitro and in vivo experiments incorporating human CRC cell lines and a new GEMM for BRAF V600E recapitulates the sessile serrated adenoma/polyp pathway seen in humans, respectively. Our findings provide compelling preclinical evidence that combination BRAF and PI3K/mTOR inhibition should be explored in clinical trials. Furthermore, our results establish a novel GEMM for investigation of the sessile serrated adenoma/polyp pathway, interrogation of BRAF V600E CRC biology, and identification of more efficacious treatment strategies.
Materials and Methods
In vitro treatment of human CRC cell lines. The following cell lines were used in this study: VACO432, RKO, VT1, T29, HCT-116 and DLD-1. VACO432, RKO, VT1, and T29 cell lines (a kind gift from B. Vogelstein) were maintained in McCoy's (Invitrogen) with 10% FBS (Invitrogen) and 1x Penicillin/Streptomycin (Invitrogen). HCT-116 and DLD-1 (ATCC) were maintained in DMEM (Invitrogen), as described above. VACO432/VT1 and RKO/T29 are isogenic pairs. activating mutation. RKO is also heterozygous for 2 frame shift mutations in NF1.
HCT-116 and DLD-1 are heterozygous for the PIK3CA H1047R activating mutation. All mutations were confirmed by DNA sequence analysis using published primers flanking each mutated exon.
After treatment with GDC-0879 (a kind gift from Genentech) and/or NVP-BEZ235 (LC Labs) for 48 hours, cell viability was measured by MTS assay, as previously described. 24 All experiments were performed a minimum of three times in quadruplicate.
Immunoblotting. Cells were lysed in lysis buffer (20 26, 27 Colonic tumors were induced using adenovirus expressing Cre recombinase (AdCre) and followed by optical colonoscopy, as previously described. 23 
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Research. (Invitrogen), as previously described. 28 Tumors were scored as MSI positive if one or more novel alleles were present in tumor but not the matched tail.
Histopathology and immunohistochemistry. Please see Supplemental Information for details
regarding histopathology and immunohistochemistry.
Results
BRAF inhibition decreases cell viability in BRAF V600E
CRC. The BRAF inhibitors PLX4032, PLX4720, and GDC-0879 have comparable mechanism and efficacy across different BRAF V600E cancer cell lines. 29, 30 We used the tool compound GDC-0879 to examine BRAF inhibition in 
32
PI3K/mTOR pathway sustains signaling after BRAF inhibition. To identify signaling pathways that might promote resistance to BRAF inhibition, we examined the PI3K/mTOR pathway. We performed western blot analyses to assess p-AKT Thr473 and p-S6 Ser240/244 in VACO432 and RKO after treatment with 0, 2, and 10 M GDC-0879 for 2 hours. While it was expected that RKO would show activation of p-AKT and p-S6 given the presence of an activating PIK3CA mutation, these studies revealed sustained p-AKT and p-S6 after BRAF inhibition in VACO432, as well, suggesting that continued PI3K/mTOR may limit the effectiveness of BRAF inhibition ( Figure 2A ). BRAF wild-type and KRAS mutant cells, VT1 and DLD-1, respectively, also showed sustained p-AKT and p-S6. Recent publications have indicated that receptor tyrosine kinases (RTKs), such as EGFR and IGFR, can become activated in the BRAF V600E cell lines following BRAF inhibitor treatment, 14, 19, 20 and therefore, the residual activity of p-AKT and p-S6 could be a result of RTK activation. To address the possibility that continued PI3K/mTOR may limit the effectiveness of GDC-0879 treatment, we examined the effects of concomitant PI3K/mTOR and BRAF inhibition by treating VACO432 and RKO with GDC-0879 and the dual PI3K/mTOR inhibitor NVP-BEZ235. NVP-BEZ235 is a potent PI3K/mTOR inhibitor in the low nanomolar range that is highly specific, as evidenced by its poor inhibition (IC50 > 5 M) of a representative panel of protein kinases. 33 Our studies revealed when the BRAF V600E cell lines VACO432 and RKO were treated with GDC-0879 at their relative IC 50 (0.5μM and 1μM, respectively), cell viability was reduced by 50%. When 1nM of NVP-BEZ235 was added in combination with GDC-0879, the overall cell viability was further reduced to 29% and 43%, respectively, as compared to untreated cells ( Figure 2B ). Comparison of combination drug therapy to single agent treatment revealed a significant difference (p < 0.05) in both cell lines. Western blot analyses indicated that combination treatment is associated with decreased MAPK and PI3K/mTOR signaling in the BRAF V600E cell lines, while combination treatment has no effect on MAPK signaling in BRAF wild-type or KRAS mutant cells ( Figure 2C ). These findings suggest that PI3K/mTOR signaling provides resistance to BRAF inhibition, which can be abrogated by concurrent BRAF and PI3K/mTOR blockade.
Concurrent BRAF and PI3K/mTOR blockade results in induction of apoptosis.
To assess the effects of combined PI3K/mTOR and BRAF inhibition on apoptosis, we examined caspase-3 activity after treatment of BRAF V600E (VACO432 and RKO) and BRAF/KRAS wild-type (VT1 and T29) cells with 2μM GDC-0879 and 100nM NVP-BEZ235 for 16 hours. This revealed a significant 1.8 and 3.0-fold induction of caspase-3 activity as compared to untreated cells after combination treatment in the BRAF mutants VACO432 and RKO, respectively (P < 0.05, Figure   2D ). Comparison of combination drug therapy to single agent treatment revealed a significant difference (p < 0.05) in the RKO cell line. However, similar analysis of the RKO cell line revealed a trend towards increased apoptosis that was not statistically significant (GDC-0879 vs. combination, P < 0.00 and NVP-BEZ235 vs. combination, P < 0.001). These findings suggest Figure 1) . 26, 27 We performed this procedure in 192 mice, which resulted in distal colonic tumor formation in 178 animals (93%). Following AdCre injection, we used colonoscopy to monitor development of individual tumors, which revealed significantly faster growth in Apc-Braf than in mice bearing floxed Apc alleles alone (Apc) (P < .0001) ( Figure 3A) . Furthermore, we observed that the mean tumor multiplicities in Apc-Braf and Apc mice were 2.25 and 1.45, respectively (P < .0001, Figure 3B ). MSI testing in ten individual colonic tumors using pyrosequencing of a microsatellite locus after PCR amplification for a specific mononucleotide repeat revealed no allelic size variations, demonstrating that these tumors are MSS (data not shown). Western blot and immunohistochemistry confirmed increased MAPK signaling in Apc-Braf tumors ( Figure 3C ). These results suggest that our strategy results in a reproducible, robust GEMM for MSS BRAF V600E CRC. 
Apc
epithelium and crypt hyperplasia, it does not reliably result in adenoma or carcinoma formation. 34 Since human BRAF V600E mutant adenomas display evidence of Wnt activation, we sought to determine if tumors from our Apc-Braf GEMM would recapitulate the sessile serrated CRC pathway in humans. We examined 36 tumors from Apc-Braf mice at 8 to 24 weeks after AdCre infection and observed 1) discrete foci with architectural abnormalities of gland serration, gland branching, basal dilatation, lateral gland extension, and dystrophic goblet cells, which are consistent with human sessile serrated adenoma/polyp (SSA/P) and 2) SSA/P with cytologic dysplasia, which is characteristic of SSA progression in humans. 35, 36 We examined 20 tumors from mice at 25 or more weeks after AdCre infection and in 10 (50%) of these mice observed SSA/P with adenocarcinoma ( Figure 4A ). Of these, 16 tumors were flat or laterally spreading with central depression on endoscopic and gross examination ( Figure 4B ). Four of these tumors exhibited evidence of invasive adenocarcinoma ( Figure 4C ). Finally, we observed lesions with epithelial serration, mucin depletion in the upper polyp, and straight, mucin-depleted bases, which are consistent with hyperplastic polyps ( Figure 4D ). No serration was seen in 40 tumors from mice bearing only the modified Apc allele (Supplemental Figure 2) . Taken together, these results suggest that our GEMM model is a robust surrogate for the human sessile serrated adenoma-carcinoma pathway. significantly increased during treatment (32.6% vs. 51.4%, P = 0.017), the mean TSI in the GDC-0879-treated cohort did not (27.5% vs. 27.7%, P = 0.95; Figure 5B ). CRC. To examine the effects of in vivo BRAF inhibition on MAPK and PI3K/mTOR signaling, we performed western blot analysis and immunohistochemistry for p-ERK, p-AKT, and p-S6 in Apc-Braf tumors. These studies revealed a decrease in p-ERK levels is seen in tumor lysates following treatment with GDC-0879, but sustained p-AKT and p-S6 levels ( Figure 5C ). These results demonstrate that in vivo BRAF inhibition results in MAPK blockade and sustained PI3K/mTOR signaling.
In vivo BRAF blockade inhibits tumor growth in
In vivo BRAF inhibition blocks proliferation but does not induce apoptosis.
We next sought to determine whether the observed tumor stasis after in vivo BRAF inhibition derived from effects on tumor proliferation and/or induction of apoptosis. To assess the effects of in vivo BRAF inhibition on cellular proliferation, we performed immunohistochemistry for the proliferation marker KI-67, which revealed a 71% decrease (P < .05). To assess the effects of in vivo BRAF inhibition on cellular apoptosis in colonic tumors, we used an in situ TUNEL assay that revealed a non-significant 1.9-fold increase (P = 0.08, Figure 5D ). These results suggest that in vivo BRAF blockade results in tumor stasis primarily through a decrease in tumor proliferation. Figure 5B ). These results demonstrate that concomitant PI3K/mTOR blockade enhances the effects of in vivo BRAF inhibition. 
Concomitant in vivo BRAF and PI3K/mTOR blockade results in inhibition of
Concomitant in vivo BRAF and PI3K/mTOR inhibition blocks proliferation and induces
apoptosis. We next sought to determine whether the observed colonic tumor regression after in vivo BRAF inhibition and PI3K/mTOR inhibition derives from changes in proliferation and/or apoptosis. To assess the effects of in vivo BRAF and PI3K/mTOR inhibition on proliferation, we used immunohistochemistry analysis for the proliferation marker KI-67, which revealed a 87% decrease (P < 0.01). To assess the effects of in vivo BRAF inhibition on apoptosis, we used an in situ TUNEL assay that revealed a statistically significant five-fold induction with concomitant BRAF and PI3K/mTOR blockade (P < 0.05, Figure 5D ). These results suggest that the observed tumor regression after concomitant BRAF and PI3K/mTOR inhibition derives from a significant decrease in proliferation and induction of apoptosis.
Discussion
Due to the extremely poor prognosis for patients with BRAF V600E CRC, the development of novel therapies for this clinical segment is urgently needed. 3, 4 The limited response of BRAF V600E CRC to vemurafenib suggests the presence of de novo or rapidly acquired resistance mechanisms. 17 Besides the de novo resistance seen in BRAF V600E CRC towards single-agent BRAF-inhibition, the MAPK pathway can be reactivated by additional mechanisms. For example, two publications have reported it is the increased activity of phospho-EGFR that follows BRAF-inhibition in CRC that leads to reactivation of p-ERK. 19, 20 Similar findings have been observed in in vivo melanoma xenograft models of acquired resistance and in in vitro CRC systems. 14, 16 Additionally, elevated levels of RAS-GTP, CRAF, and pAKT have been found in melanoma that
Research. and inactivated Apc in the distal colon of floxed mice using AdCre, as we have previously described. 23, 24 In these mice, we observed early sessile serrated adenoma/polyp (SSA/P), SSA/P with cytologic dysplasia, SSA/P with adenocarcinoma, and invasive carcinoma. These findings demonstrate that we are able to recapitulate the histopathologic spectrum of the sessile serrated adenoma-carcinoma pathway seen in humans, making this a robust surrogate for BRAF V600E CRC.
Cancer GEMMs that are robust preclinical drug testing platforms should present with the following features: 1) tumors develop rapidly along a reproducible time line and 2) tumors can be continuously monitored throughout drug treatment. Because of the association between BRAF mutation and activation of the Wnt pathway in human CRC, we began with conditional Apc-Braf mice to accelerate tumorigenesis. 36, 38 To enable the use of optical colonoscopy for longitudinal tumor evaluation, we focally modify floxed genes in the distal colon using AdCre, as we have 
previously described. 23, 24 As such, these tumors reproducibly progress in the distal colon, permitting monitoring by optical colonoscopy throughout experimental drug treatments. Our GEMM fulfills the above requirements, making it a robust platform for evaluation of experimental therapeutics.
In both our in vitro and our in vivo data utilizing our novel BRAF V600E GEMM, we corroborate the findings seen in human patients: BRAF mutant tumors are not sensitive to single-agent BRAF inhibition. As tumor growth is modulated by complex, interdigitating signaling networks, blockade at a single node often results in compensation through a parallel pathway. Recently, publications have indicated that in the presence of a BRAF inhibitor, the MAPK pathway can be re-activated by the expression of RTKs. 14, 19 In contrast, the PI3K pathway shows sustained activity in 60% of treatment-naive BRAF V600E CRC, which may explain the ineffectiveness of BRAF inhibitors. 22 Consequently, concurrent inhibition of both pathways may be required. For example, chronic BRAF inhibition has been suggested to confer drug resistance in BRAF V600E melanoma through recruitment of PI3K signaling, while simultaneous blockade of both signaling pathways results in effective treatment. 27, 29 Furthermore, the requirement for concomitant inhibition of the MAPK and PI3K/mTOR pathways has been shown in other cancer models. [40] [41] [42] To examine if this feature were present in our model for BRAF heterozygous for a P124T mutation, this has to our knowledge not been characterized as an activating mutation. Taken together with the significant proportion of BRAF V600E CRC patients with sustained PI3K/mTOR activity, 22 we believe that the need for combination therapy is independent of PIK3CA mutational status Our subsequent in vitro and in vivo studies showed that combined BRAF and PI3K/mTOR inhibition is required for effective treatment of BRAF V600E CRC. While it has been suggested that NVP-BEZ235 is a more potent mTOR inhibitor than an PI3K inhibitor, 43 inhibition of this particular signaling node seems to be critical to the successful treatment of BRAF V600E CRC. As we did not test this directly, we cannot say whether pure PI3K inhibitors or pure mTOR inhibitors will be as or more effective in combination with BRAF inhibition. However, the more potent mTOR inhibition seen by the down regulation of p-S6 with NVP-BEZ235 may suggest this to be a more important component. To our knowledge, we are the first to show a BRAF inhibitor-based combination therapy that effectively down regulates TORC1, as evidenced by down regulation of p-S6. Additionally, others have also reported the need for a combinational approach. It has been reported that combination treatment with a RAF inhibitor (RAF265) and a dual PI3K/mTOR inhibitor (BEZ) is effective in thyroid cancer. To maximize tumor regression, robust strategies for induction of apoptosis are critical. Whereas BRAF inhibition alone is sufficient to induce apoptosis in melanoma, 45 such treatment results in only growth arrest of BRAF V600E thyroid and colon cancers 44, [46] [47] [48] [49] with resistance to cell death. 41 This suggests that differential apoptotic responses are one underlying mechanism of the disparate clinical outcomes seen in melanoma and CRC patients treated with BRAF inhibitors. In our experiments, the effects on apoptosis may have appeared more pronounced in RKO because it harbors a prototypic PIK3CA activating mutation (H1047R), whereas VACO432 contains a rare and uncharacterized PIK3CA mutation (P124T) that might possess lower intrinsic activity.
Furthermore, we examined apoptosis after 16 hours, as this has been reported to be the time of maximal apoptotic induction by agents such as staurosporine. It is possible that examination at a different time point might further augment the differences in VACO432 cells to achieve statistical significance. Nonetheless, our data suggest that concomitant treatment of BRAF V600E CRC cell lines with NVP-BEZ235 may be important to tip the scales from inhibition of proliferation towards induction of apoptosis. Furthermore, concomitant BRAF and PI3K inhibition has been observed to increase the sensitivity of CRC to TRAIL treatment. 
